Infectious scleritis after a diabetic foot ulcer.
Maskin
S L
SL
D000284:Administration, Oral; D000287:Administration, Topical; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000503:physiopathology; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004917:Erythromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000209:etiology*; D016523:Foot Ulcer / Q000150:complications*; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015423:Scleritis / Q000188:drug therapy / Q000209:etiology*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*
D002939:Ciprofloxacin; D004917:Erythromycin; D014640:Vancomycin; D014031:Tobramycin